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Purpose:

To examine whether cardiac chemical exchange saturation
transfer (CEST) imaging can be serially and noninvasively
used to probe cell survival or rejection after intramyocardial implantation in mice.

Materials and
Methods:

Experiments were compliant with the National Institutes
of Health Guidelines on the Use of Laboratory Animals
and approved by the Institutional Animal Care and Use
Committee. One million C2C12 cells labeled with either
europium (Eu) 10-(2-hydroxypropyl)-1,4,7-tetraazacyclododecane-1,4,7-triacetic acid (HP-DO3A) or saline via
the hypotonic swelling technique were implanted into the
anterior-lateral left ventricular wall in C57BL/6J (allogeneic model, n = 17) and C3H (syngeneic model, n = 13)
mice. Imaging (frequency offsets of 615 parts per million)
was performed 1, 10, and 20 days after implantation, with
the asymmetrical magnetization transfer ratio (MTRasym)
calculated from image pairs. Histologic examination was
performed at the conclusion of imaging. Changes in MTRasym
over time and between mice were assessed by using twoway repeated-measures analysis of variance.

Results:

MTRasym was significantly higher in C3H and C57BL/6J
mice in grafts of Eu-HP-DO3A–labeled cells (40.2% 6 5.0
vs 37.8% 6 7.0, respectively) compared with surrounding
tissue (20.67% 6 1.7 vs 21.8% 6 5.3, respectively; P ,
.001) and saline-labeled grafts (20.4% 6 6.0 vs 21.2% 6
3.6, respectively; P , .001) at day 1. In C3H mice, MTRasym
remained increased (31.3% 6 9.2 on day 10, 28.7% 6
5.2 on day 20; P , .001 vs septum) in areas of in Eu-HPDO3A–labeled cell grafts. In C57BL/6J mice, corresponding MTRasym values (11.3% 6 8.1 on day 10, 5.1% 6 9.4
on day 20; P , .001 vs day 1) were similar to surrounding
myocardium by day 20 (P = .409). Histologic findings confirmed cell rejection in C57BL/6J mice. Estimation of graft
area was similar with cardiac CEST imaging and histologic
examination (R2 = 0.89).

Conclusion:

Cardiac CEST imaging can be used to image cell survival
and rejection in preclinical models of cell therapy.
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EXPERIMENTAL STUDIES: Tracking of Cell Survival or Rejection in Mouse Models of Cell Therapy

O

ver a decade of investigation
into cardiac regeneration with cell
therapy has demonstrated limited
regenerative capacity due to low survival of injected cells (1). The inability
to track in vivo cell fate, including survival or rejection without using ex vivo
tissue staining, remains an obstacle to
further progress, including the development of methods to enhance cell
survival (2). Magnetic resonance (MR)
imaging is used for in vivo imaging of
infarct healing through characterization of cardiac structure, function, perfusion, and fibrosis (3). MR imaging
cell tracking in cell therapy with iron

Advances in Knowledge
nn Cardiac chemical exchange saturation transfer (CEST) MR imaging can be used to serially
image the fate of implanted cells
in preclinical models of cell
therapy.
nn CEST contrast (change in signal
intensity), measured as the
asymmetrical magnetization
transfer ratio, is preserved in
surviving paramagnetic CESTlabeled cells for 20 days after
cardiac implantation in C3H mice
(28.75 6 5.2 for cell graft vs
1.4% 6 5.6 for septum, P ,
.001).
nn CEST contrast is eliminated in
rejected paramagnetic CESTlabeled cells within 20 days after
implantation in C57BL/6J mice
(5.1% 6 9.4 for cell graft vs
1.1% 6 4.5 for septum, P = .41).
nn Measurement of CEST contrast
can be used to differentiate surviving cells from those undergoing rejection as early as 10
days after implantation (31.3% 6
9.2 for surviving cells vs 11.3%
6 8.1 for cell rejection, P ,
.001).
nn Assessment of graft size at cardiac CEST MR imaging demonstrates a positive association with
graft size according to histologic
findings (R2 = 0.89, covariance =
17%).
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oxide nanoparticle–labeled cells (4–7)
has raised concerns of altered gene
expression, tissue retention of particles after cell death, and difficulty in
differentiating between labeled cells and
tissue necrosis (2,8–13).
Chemical exchange saturation transfer (CEST) MR imaging is an emerging
molecular imaging technique wherein
the contrast (change in signal intensity)
of either paramagnetic CEST agents
(14,15) or CEST-active reporter genes
(16–18) is selectively activated by using radiofrequency irradiation at target
specific offset frequencies (19). Subsequently, paramagnetic CEST–labeled
cells or CEST MR imaging reporter
gene–expressing cells can be visualized without disruption of underlying
MR image integrity. Prior CEST MR
imaging studies have been conducted
to track paramagnetic CEST–labeled
cells in subcutaneous tumor models in
mice (14,15) and image CEST reporter
gene–expressing cells implanted in the
rodent brain (16–18). While CEST
MR imaging is suited for cell tracking
in cardiac cell therapy, conventional
CEST approaches are unsuitable for
preclinical cardiac imaging and have
been limited to stationary organs and
the lungs (20). Recently, we designed
a CEST MR imaging method specifically for preclinical cardiac imaging,
termed cardiac CEST imaging (21,22)
and demonstrated the ability to visualize paramagnetic CEST–labeled cells
24 hours after intramyocardial implantation (22).
In this study, we used two mouse
models of cardiac cell therapy: one syngeneic model in which implanted cells
derived from the same genetic strain of
mice survive and proliferate over time
(C3H genetic background) and one allogeneic model in which identical cells
implanted into mice on a different genetic background (C57BL/6J) undergo
complete rejection after implantation.
We hypothesized that CEST contrast
generated by paramagnetic CEST–labeled cells is preserved in surviving cell
grafts and eliminated in instances of cell
rejection. The purpose of this study was
to examine whether cardiac CEST can
serially and noninvasively be used to

demonstrate cell survival or rejection
after intramyocardial implantation in
mice.

Materials and Methods
Cell Culture and Labeling
Immortalized mouse skeletal myoblasts
(C2C12) were labeled with either europium (Eu) 10-(2-hydroxypropyl)-1,4,7tetraazacyclododecane-1,4,7-triacetic
acid (HP-DO3A, provided by Dr Silvio
Aime at the University of Turin, Turin,
Italy) or saline by using a hypotonic
swelling technique (23). For control experiments, cells were exposed to hypotonic solution with saline substituted for
Eu-HP-DO3A solution. Full details of cell
culture and labeling can be found in
Appendix E1 (online).
Cell Transplantation
Experiments were performed according to the National Institutes of Health
Guidelines on the Use of Laboratory
Animals and were approved by the Institutional Animal Care and Use Committee. Cardiac implantation of cells
involved the use of the “pop-out” technique (24). Mice were anesthetized and
maintained with 2% isoflurane in oxygen,
the pectoral muscles were dissected at
the fourth intercostal space, mosquito
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Mouse Models
A total of 17 male C57BL/6J mice and
13 C3H mice (The Jackson Laboratory,
Bar Harbor, Maine) were used. Mice
from both genetic strains underwent
transplantation of either cells labeled
with Eu-HP-DO3A or saline-labeled
control cells (Table). Imaging was performed 1 week before cell transplantation
and 1, 10, and 20 days after cell transplantation, after which hearts were excised, sectioned, and stained by using
hematoxylin-eosin. Separately, the cellular fraction of murine macrophages
was quantified from tissue sections
from C3H (n = 2) and C57BL/6J (n = 2)
mice that received Eu-HP-DO3A–labeled
cells via immunostaining (Appendix
E1 [online]) with a rat antimouse F4/80
antibody (clone BM8, catalog no. 14–
4801–85; eBioscience, San Diego, Calif).
C2C12 cells are derived from C3H mice
(syngeneic model) and will survive and
proliferate after implantation in C3H
mice but undergo rejection (allogeneic
model) in C57BL/6J mice.

Biospin MR Imaging, Ettlingen, Germany) by using a cylindrical volume coil for
excitation (outer diameter, 11.2 cm; inner diameter, 8.6 cm) and a four-channel
phased-array surface coil for detection.
Anesthesia involved the use of 1.5% isoflurane in oxygen, and body temperature
was maintained (at 37°C) by using circulating water. Electrocardiographic and
respiratory gating was performed with
a Small Animal Instruments system
(SAI, Stonybrook, NY). The site of
cell injection was identified 1 day after implantation as areas of disrupted
pericardium on long-axis images. For
subsequent imaging, the same section
location was identified by using the
distance from the left ventricular apex
and anatomic features, including papillary muscles. To further ensure that
data were repeatedly acquired in the
same section location, pairs of cardiac CEST images were acquired in
two to three sections around the initial site. Briefly, the cardiac CEST pulse
sequence uses a constant repetition
time gradient-echo readout to drive initial CEST weighting into the steady-state
longitudinal magnetization of the myocardium (22). The acquisition of cine
images is electrocardiographically and
respiratory gated, with dummy excitation pulses maintaining steady-state
conditions. This strategy enables reliable CEST imaging of the rapidly beating mouse heart in the presence of free
breathing. Imaging parameters included
field of view, 2.56 3 2.56 cm; matrix,
256 3 128; true in-plane resolution, 200 3
100 mm; section thickness, 1 mm; repetition time (msec)/echo time (msec),
6.92/3.42; four signals acquired; and
15° flip angle. For CEST saturation, a
train of spatially nonselective Gaussian
pulses (8.8 msec; 200-Hz bandwidth;
1-msec interpulse delay; number of pulses, 196; flip angle, 720°; and mean induced transverse magnetic field, or B1,
14 mT) was applied at offset frequencies
of 615 parts per million (ppm). The total acquisition time was 2.5–3.0 minutes
per cine image or 5–6 minutes per pair.

Imaging
Imaging was performed with a 7-T horizontal imaging unit (ClinScan; Bruker

Data Analysis
Data analysis was performed in Matlab version R2012b (The MathWorks,

Sample Sizes for Four Experimental
Cohorts Used in the Study
Cell Type
Eu-HP-DO3A–
labeled cells
Saline-labeled
control cells

C3H
(n = 13)

C57BL/6J
(n = 17)

n=6

n=8

n=7

n=9

clamps were used to open the pleural
membrane, and the heart was pressed
toward the surface while maintaining
pressure on the thorax. Approximately
106 cells in 10 mL were injected into the
anterior-lateral left ventricular midwall by
using a 27-gauge needle. Afterward, the
heart was returned to the intrathoracic
space, followed by evacuation of air and
incision closure to prevent pneumothorax. The mice were removed from anesthesia and allowed to recover in room air.
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Natick, Mass) by using custom-built
software. For each mouse and time
point, one section was selected from
acquired data to ensure consistent
section position across time points.
The end-diastolic image acquired after saturation at 15 ppm was registered to the corresponding image acquired after saturation at 215 ppm.
Maps of the asymmetrical magnetization transfer ratio (MTRasym) were
then calculated on a voxelwise basis as
MTRasym = [(S-15 ppm – S15 ppm)/S-15 ppm]
· 100. Maps of MTRasym are processed
such that only voxels from the left ventricle are superimposed on corresponding magnitude reconstructed images.
On the basis of our previous findings,
regions of interest that encompassed
the cell graft were defined on day 1
by using a threshold MTRasym value of
up to 15% for mice that received EuHP-DO3A–labeled cells (22). At subsequent time points, the same regions of
interest were applied by using anatomic
details, such as papillary muscles and
polar distance from right ventricular
insertion points, to guide placement.
For mice that received saline-labeled
cells, a region of interest was defined retrospectively on the appropriate section on the basis of histologic
identification of the cell graft for C3H
mice and the identification of the injection site for C57BL/6J mice. Finally, in all mice, an internal control
measurement was obtained in the interventricular septum on the section
that contained injected cells.

Estimation of Graft Size
Cardiac CEST measurement of graft
size was performed on data acquired
20 days after implantation of Eu-HPDO3A–labeled cells. On the basis
of our prior findings of appropriate
threshold values for identifying cell
grafts, an MTRasym threshold of up to
15% was used to calculate graft size as
a percentage of total myocardial area
(22). Corresponding measures from hematoxylin-eosin–stained tissue sections
were calculated by manually contouring
blue-stained graft tissue and were expressed as a percentage of total myocardial area.
133
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Statistics
Statistical analysis was performed with
SigmaPlot version 13 software (Systat
Software, San Jose, Calif). Comparison of MTRasym values between EuHP-DO3A–labeled cell grafts, septal regions, and saline-labeled cell
grafts and values over time was performed by using two-way repeatedmeasures analysis of variance, with
pairwise comparisons made by using
the Holm-Sidak method, which was also
used for comparison of MTRasym values
over time in Eu-HP-DO3A–labeled cell
grafts between C3H and C57BL/6J mice.
The Student t test was used to compare MTRasym measurements prior to
cell implantation and to compare quantification of graft size according to histologic findings. The association of graft
size between MR imaging and histologic findings was examined by using
Bland-Altman analysis. A Shapiro-Wilk
test was used to confirm the normal
distribution of all data. A P value of less
than .05 was used to indicate a significant difference.

Pumphrey et al

Figure 1

Results
CEST imaging of the heart with the parameters selected for this study yielded
a mean signal-to-noise ratio 6 standard
deviation of 19.8 arbitrary units (a.u.) 6
4.1 and contrast-to-noise ratios of 7.3
a.u. 6 2.9 and 7.3 a.u. 6 5.6 between
myocardium and blood or lung, respectively. The mean MTRasym values
measured in the anterior-lateral wall
(20.3% 6 1.9 for C3H vs 21.5% 6 1.1
for C57BL/6J, P = .608) and in the septum (1.8% 6 2.2 for C3H vs 0.6% 6
1.1 for C57BL/6J, P = .595) prior to cell
transplantation were similar in C3H
(n = 7) and C57BL/6J (n = 5) mice (representative images are shown in Fig E1
[online]). The mean heart rates during
the study time course were 499 beats
per minute 6 76 and 513 beats per minute 6 63 for C3H and C57BL/6J mice,
respectively. Repeated imaging of C3H
mice in which implanted C2C12 cells
survived demonstrated significantly
increased MTRasym values in grafts
of Eu-HP-DO3A–labeled cells compared with surrounding myocardium.
134

Figure 1: (a, b) Longitudinal cardiac CEST images of the survival of Eu-HP-DO3A–labeled cells in C3H
mice. Twenty-four hours after implantation (a), significantly increased MTRasym values were observed adjacent
to the inferior papillary muscle (arrow), corresponding to the location of Eu-HP-DO3A–labeled cells. After
20 days (b), increased MTRasym was still observed in the same myocardial region surrounding the inferior
papillary muscle (arrow). The proliferation of labeled cells and the likely dilution of Eu-HP-DO3A with cell
division reduced the MTRasym values of the graft relative to day 1. (c) Photomicrograph (hematoxylin-eosin
stain; original magnification, 34) of the corresponding histologic slice demonstrates a graft of proliferating
cells (blue) adjacent to the inferior papillary muscle in a similar location to increased MTRasym values seen on
b. (d) Higher magnification photomicrograph (hematoxylin-eosin stain; original magnification, 320) of the
area on c enclosed within the black box demonstrates the presence of proliferating cells (arrows) near the
endocardial surface at the boundary of the papillary muscle.

Representative MTRasym maps acquired
1 and 20 days after implantation and
corresponding histologic images (Fig 1)
demonstrate the capacity to identify
surviving Eu-HP-DO3A–labeled cells on
the basis of increased CEST contrast at
15 ppm. Identical imaging of C57BL/6J
mice, in which implanted cells underwent rejection, demonstrated increased
MTRasym values in the area of implanted
Eu-HP-DO3A–labeled cells 24 hours
after implantation (Fig 2). However,
rejection of labeled cells and clearance

of Eu-HP-DO3A eliminated the previously observed CEST contrast in areas
of implanted cells within 20 days and
was confirmed at histologic examination
(Fig E2 [online]). In both C3H and
C57BL/6J mice, the implantation of
saline-labeled (control) C2C12 cells did
not result in any change in CEST contrast in areas of either surviving cells or
rejected cells (Fig E3 [online]).
Repeated measurement of MTRasym
in areas of implanted cells and internal septal control regions demonstrated

radiology.rsna.org
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Figure 2

Figure 2: Cardiac CEST images show how the rejection of implanted Eu-HP-DO3A–labeled cells in
C57BL/6J mice leads to elimination of initial CEST contrast. (a) Implantation of Eu-HP-DO3A–labeled cells
in a representative C57BL/6J mouse resulted in increased MTRasym values in the lateral ventricular wall in
close proximity to the inferior papillary muscle 24 hours after implantation (arrow), similar to that observed in
C3H mice. (b) However, at 20 days after implantation, MTRasym values in the same myocardial region (arrow)
decreased and were indistinguishable from surrounding myocardium.

Figure 3

Figure 3: Bar graphs illustrate the measurement of MTRasym, which allows differentiation of (a) cell survival
from (b) cell rejection. In C3H mice (a), MTRasym values in the region that contains Eu-HP-DO3A–labeled cells
(cell graft) were significantly higher compared with septal regions (septum) in the same hearts and compared
with corresponding regions after implantation of saline-labeled control cells (saline graft) in genetically identical mice at all measured time points. By 20 days after implantation, the mean MTRasym values in cell grafts
were significantly lower when compared with values 1 day after implantation. In C57BL/6J mice (b), MTRasym
values were increased 1 day after implantation in areas of Eu-HP-DO3A–labeled cells when compared with
septal regions and saline-labeled controls and remained significantly increased 10 days after implantation
but were similar 20 days after implantation. By 10 days, MTRasym values in the region of implanted Eu-HPDO3A–labeled cells were significantly reduced compared with both the initial values 1 day after implantation
and the corresponding values in C3H mice at identical time points. Bars represent P values less than .05 at
identical time points. ∗ 5 P , .05 versus day 1 in the same region, † = P , .05 versus cell graft in C3H
mice at the same time point.

different patterns for surviving cells
when compared with cells undergoing
rejection (Fig 3). In C3H mice, the CEST
contrast in tissue regions containing
Eu-HP-DO3A–labeled cells remained
significantly
increased
throughout
the time course of examination in
Radiology: Volume 282: Number 1—January 2017
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comparison to internal control regions of interest in the septum and
in comparison to regions of interest that contained implanted salinelabeled cells in genetically identical
mice (Fig 3). Within regions of Eu-HPDO3A–labeled cells, MTRasym values
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declined gradually after implantation
and were significantly reduced by
20 days after implantation compared
with initial measurements (Fig 3). In
C57BL/6J mice, CEST contrast was
significantly increased within grafts of
Eu-HP-DO3A–labeled cells 1 day after
implantation when compared with septal regions of interest and saline-labeled
cell grafts (Fig 3). However, MTRasym
values within regions of labeled cell
grafts decreased significantly within 10
days of implantation. By 20 days after
implantation, MTRasym values were indistinguishable from either surrounding
myocardium (P = .409) or saline-labeled control animals (P = .254). MTRavalues within Eu-HP-DO3A–labeled
sym
cell grafts were statistically similar (P =
.564) in C3H and C57BL/6J mice 1 day
after implantation but were significantly
(P , .001) lower in C57BL/6J mice 10
and 20 days after implantation (Fig 3).
The survival or rejection of C2C12
cell grafts was confirmed by hematoxylineosin staining and assessed as the percentage of total left ventricular myocardial area. In C3H mice, surviving C2C12
cells resulted in similar graft sizes in
Eu-HP-DO3A and saline-labeled cell
grafts (12.0% 6 3.3 for Eu-HP-DO3A
vs 12.9% 6 9.3 for saline, P = .825).
The rejection of C2C12 cell grafts in
C57BL/6J mice was similar for both EuHP-DO3A and saline-labeled cells (1.0%
6 1.0 for Eu-HP-DO3A vs 0.7% 6
0.5 for unlabeled cells, P = .409). Assessment of Eu-HP-DO3A–labeled graft
size was similar between cardiac CEST
imaging and histologic examination for
most grafts but was underestimated by
using MR imaging for grafts larger than
12% of ventricular mass (Fig 4). The
coefficient of variation in calculation of
graft size was 17%. Staining of isolated
tissue sections for murine macrophages
(Fig 5) demonstrated that F4/80-positive macrophages accounted for 1.2% 6
0.3 and 0.9% 6 0.1 of the cells in the
graft regions for C3H and C57BL/6J
mice, respectively.

Discussion
The results of this study demonstrate
the application of cardiac CEST MR
135
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Figure 4

Figure 4: Plots show the comparison of graft size according to cardiac CEST imaging and histologic
findings. (a) The quantification of graft size measured as a percentage of left ventricular (LV ) myocardial area
according to cardiac CEST imaging across all mice in which Eu-HP-DO3A cells were implanted demonstrated
association with corresponding histologic measurements. (b) Bland-Altman analysis demonstrated close
agreement in graft size, with slight underestimation of graft size according to MR imaging in grafts larger
than 12% of left ventricular area.

Figure 5

Figure 5: Photomicrographs show macrophage staining in C3H cardiac tissue. (a) Nuclear staining (496diamidino-2-phenylindole·2HCl, or DAPI; original magnification, 340 composite) of a cross-section of
cardiac tissue from a mouse that underwent implantation of Eu-HP-DO3A–labeled C2C12 cells. (b) Photomicrograph with higher magnification of a region of interest within the cell graft (original magnification, 3400
composite) is shown after immunostaining for murine macrophages (F4/80, red) and cell nuclei (DAPI, blue).
Murine macrophages (arrow) were not present in high numbers in C3H cardiac tissue 20 days after cell
implantation. Corresponding images from a C57BL/6J mouse are found in Figure E4 (online).

imaging for serial tracking of cell survival or rejection after cardiac transplantation. In both models, grafts of
viable Eu-HP-DO3A–labeled cells were
clearly distinguishable from surrounding myocardium immediately after implantation. The implantation of salinelabeled cells as controls resulted in no
changes in MTRasym values, regardless
of cell fate and time. While tissues that
contained surviving Eu-HP-DO3A–labeled cells demonstrated preserved
CEST contrast for 20 days, the rejection of identical cells led to immediate
reductions in MTRasym by 10 days after
136

implantation and complete loss of CEST
contrast within 20 days. Finally, assessment of graft size by applying a threshold
MTRasym value was similar to that measured at histologic examination.
Myocardial implantation of C2C12
cells is an established cardiac cell therapy model for evaluating MR imaging
cell-tracking techniques (13,25,26). In
a prior study, transgenic ferritin heavychain overexpressing C2C12 cells implanted into the hearts of C3H mice
were visualized by using T2*-weighted
MR imaging 3 weeks after implantation
(25). We observed similar engraftment

of C2C12 cells in C3H mice by 20 days
after implantation. Importantly, labeling of C2C12 cells with Eu-HP-DO3A
generated robust CEST contrast at the
time of implantation that was preserved
throughout the course of our study and
did not affect the growth rate of C2C12
grafts. By 20 days after implantation,
the moderate reduction in MTRasym values
in Eu-HP-DO3A–labeled grafts likely
resulted from dilution of label with cell
division, which presents a boundary
condition for the detection of surviving
cells. In our study, we did not observe
an eventual loss of CEST contrast; however, we were unable to perform continued examination beyond 20 days after implantation owing to an increase
in arrhythmias and death caused by the
growth of C2C12 grafts.
MR imaging tracking of cells after
cardiac transplantation was previously
widely explored via iron oxide nanoparticle labeling; however, tissue retention
of nanoparticles for up to 6 weeks after the death of labeled cells results
in inaccurate detection of cell survival
(2,8–13). In this study, the rejection of
Eu-HP-DO3A–labeled C2C12 cells in
C57BL/6J mice resulted in rapid loss
of CEST contrast. The clearance of
Eu-HP-DO3A from myocardium after
intravenous injection was previously
demonstrated by using dynamic measurement of cardiac MTRasym for 30
minutes after injection (21). In Eu-HPDO3A–labeled cells undergoing rejection, Eu-HP-DO3A that is released after cell rupture is likely cleared through
mechanisms similar to those observed
previously. However, in this study, we
did not examine whether removal of
Eu-HP-DO3A by means of inflammatory mechanisms contributes to MTRasym
normalization after rejection. Importantly, given renewed concerns about
the accumulation of gadolinium in regions of the brain, even in individuals
with preserved renal function (27,28),
further studies are necessary to understand clearance of paramagnetic CEST
agents after cell death.
The implantation of C2C12 cells in
C3H and C57BL/6J mice models the two
extreme outcomes of cell therapy: high
survival with rapid proliferation that
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borders on teratoma formation (C3H)
and complete rejection of implanted cells
(C57BL/6J). With existing cell therapy
approaches, near-complete rejection
of implanted cells is typically observed,
similar to that observed in our C57BL/6J
model, with an ultimate goal of increasing cell survival in the direction observed
in our C3H model. A number of combined therapeutic approaches are under
investigation, including incorporation
of biomaterials (29), combined cell and
gene therapy (30), and pharmacologic
stimulation to enhance recruitment of native mesenchymal cells (31). The ability
to noninvasively monitor the success of
secondary interventions in promoting
increased cell survival will be crucial in
pushing forward the next generation of
cell therapy approaches. While we accurately quantified the rejection of Eu-HPDO3A–labeled cells in C57BL/6J mice,
the sensitivity limits of cardiac CEST
need to be investigated further.
The use of lanthanide (Ln)-based
para
magnetic CEST agents (Ln-HPDO3A) represents a potential translational limitation, given renewed concern
surrounding similarly formulated gadolinium-based contrast agents. While the
concentration of chelated lanthanide
metals is as high as 3–5 mmol/L in cells
after hypotonic swelling (22), even the
immediate release of all intracellular
Ln-HP-DO3A into the blood pool would
result in concentrations that are orders
of magnitude lower than those that occur after intravenous injection of similar
contrast agents as part of routine MR
imaging examination (Appendix E1 [online]). Further study is warranted as
to whether labeling of cells with paramagnetic CEST agents induces changes
in gene expression similar to those observed with iron oxide–based agents.
However, emerging CEST MR imaging
labels, including CEST-active reporter
genes (16,18,32) and engineered nonmetallic CEST macromolecules (33,34),
could be used in place of lanthanide
metal-based labels. A secondary limitation to our study is the use of high radiofrequency saturation power to generate
CEST contrast that would not be possible in clinical settings. While this may
present an immediate obstacle, further
Radiology: Volume 282: Number 1—January 2017

n

development of continuous wave approaches by using multichannel parallel
transmit and receive technology will enable substantial reductions in required
saturation energy. Finally, confining
CEST imaging and histologic analysis to
a limited number of sections limited the
ability to obtain volumetric information
about graft size. A more thorough validation of graft size measurement should
be performed in a future study by comparing whole-heart cardiac CEST imaging to whole-heart histologic findings.
In conclusion, cardiac CEST cell
tracking can serve as a tool for preclinical research of emerging methods to
enhance the survival of implanted stem
cells. Since CEST contrast is selectively
activated, the combined use of CESTactive biomaterials (33), CEST MR imaging reporter genes (16,18,32), and
multiagent paramagnetic CEST labeling
of different cell populations (15) has
the potential to demonstrate multiple
processes that drive cell fate decisions
in regenerative therapy.
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